Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) FCF Margin (2018 - 2025)

Historic FCF Margin for Sunshine Biopharma (SBFM) over the last 9 years, with Q3 2025 value amounting to 7.81%.

  • Sunshine Biopharma's FCF Margin rose 144000.0% to 7.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.84%, marking a year-over-year increase of 195500.0%. This contributed to the annual value of 40.68% for FY2024, which is 39200.0% down from last year.
  • Per Sunshine Biopharma's latest filing, its FCF Margin stood at 7.81% for Q3 2025, which was up 144000.0% from 15.23% recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's FCF Margin peaked at 7.81% during Q3 2025, and registered a low of 1192.65% during Q3 2021.
  • Moreover, its 5-year median value for FCF Margin was 59.68% (2024), whereas its average is 324.89%.
  • Data for Sunshine Biopharma's FCF Margin shows a peak YoY increase of 11471300bps (in 2021) and a maximum YoY decrease of -6288900bps (in 2021) over the last 5 years.
  • Over the past 5 years, Sunshine Biopharma's FCF Margin (Quarter) stood at 366.68% in 2021, then surged by 83bps to 61.95% in 2022, then soared by 52bps to 30.04% in 2023, then fell by -22bps to 36.63% in 2024, then surged by 79bps to 7.81% in 2025.
  • Its last three reported values are 7.81% in Q3 2025, 15.23% for Q2 2025, and 19.34% during Q1 2025.